IP Library Granted Patent US 9,410,157
Granted Patent B2
US 9,410,157 · App. 13/192,058 · Granted Aug 9, 2016

Systems and methods for the secretion of recombinant proteins in gram negative bacteria

Inventors: Sydnor T. Withers, III (Madison, WI); Miguel A. Dominguez (Madison, WI); Matthew P. DeLisa (Ithaca, NY); Charles H. Haitjema (Ithaca, NY)
Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION; CORNELL UNIVERSITY
C12N15/70C12P21/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,410,157
App. No.
13/192,058
Granted
Aug 9, 2016
Kind
B2
Abstract

Disclosed herein are systems and methods for producing recombinant proteins utilizing mutant E. coli strains containing expression vectors carrying nucleic acids encoding the proteins, and secretory signal sequences to direct the secretion of the proteins to the culture medium. Host cells transformed with the expression vectors are also provided.

Claims (19)

1. A recombinant bacterium transformed with a recombinant vector comprising a first DNA sequence encoding a YebF linked to a second DNA sequence encoding a heterologous protein, wherein the mutant bacterium comprises mutations so that at least the NlpD gene product and at least one of the EnvZ, OmpR and YihF gene products are not expressed or are rendered non-functional.

2. The recombinant bacterium of claim 1 wherein the bacterium is a gram negative bacterium.

3. The recombinant bacterium of claim 2 , wherein the bacterium is selected from the group consisting of Escherichia, Salmonella, Yersinia , and Shigella.

4. The recombinant bacterium of claim 1 , wherein both the NlpD and EnvZ gene products are not expressed or are rendered non-functional.

5. The recombinant bacterium of claim 1 , wherein both the NlpD and OmpR gene products are not expressed or are rendered non-functional.

6. The recombinant bacterium of claim 1 , wherein the NlpD and YihF gene products are not expressed or are rendered non-functional.

7. An expression system for secreting a recombinant protein into a culture medium, the system comprising: (a) a mutant E. coli bacterium, wherein the NlpD gene product and at least one of the EnvZ, OmpR and YihF gene products are not expressed or are rendered non-functional; and (b) a recombinant vector comprising a first DNA sequence encoding YebF linked to a second DNA sequence encoding a heterologous protein.

8. The system of claim 7 , wherein both the NlpD and EnvZ gene products are not expressed or are rendered non-functional.

9. The system of claim 7 , wherein both the NlpD and OmpR gene products are not expressed or are rendered non-functional.

10. The system of claim 7 , wherein the NlpD and YihF gene products are not expressed or are rendered non-functional.

11. The system of claim 7 , wherein the at least one gene product is not expressed or is rendered non-functional by deleting all or part of the gene encoding the gene product.

12. The system of claim 7 , wherein the at least one gene product is not expressed or is rendered non-functional by way of alteration of a promoter control sequence.

13. The system of claim 7 , wherein said recombinant vector further comprises an inducible promoter sequence element.

14. The system of claim 7 , wherein said recombinant vector further comprises a repressor element.

15. The system of claim 7 , wherein the heterologous protein that is secreted is biologically active.

16. The system of claim 7 , wherein the heterologous protein is selected from the group consisting of: a cellulase, a protease, a lipase, a cutinase, an amylase, a galactosidase, a pullulanase, a glucose isomerase, a protein disuphide isomerase, a cyclodextrin gluconotransferase, a phytase, a glucose oxidase, a glucosyl transferase, laccase, bilirubin oxidase, a xylanase, an antigenic microbial or protozoan protein, a bacterial protein toxin, a viral protein, and a pharmaceutical.

17. The system of claim 7 , wherein the heterologous protein is selected from the group consisting of an immunoglobulin light chain, an immunoglobulin heavy chain, an immunoglobulin light chain fragment or an immunoglobulin heavy chain fragment.

18. The system of claim 7 , wherein the expression of both DNA sequences is under the control of an inducible promoter.

19. The system of claim 18 , wherein the inducible promoter is a lac promoter.

Assignments (4)
CONFIRMATORY LICENSE Recorded May 14, 2014
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: ENERGY, UNITED STATES DEPARTMENT OF
Reel/Frame 032901/0746 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2011
From: DELISA, MATTHEW; HAITJEMA, CHARLES H.
To: CORNELL UNIVERSITY
Reel/Frame 027042/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2011
From: WITHERS, SYDNOR, III
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 027007/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2011
From: DOMINGUEZ, MIGUEL
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 027007/0134 →
Continuity (2)
Provisional Application 61369188 · Jul 30, 2010
Related Publication 20120225453A1 · Sep 6, 2012